NWD2 Human Pre-designed siRNA Set A contains three designed siRNAs for NWD2 gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

NXF1 Human Pre-designed siRNA Set A contains three designed siRNAs for NXF1 gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

NXF2 Human Pre-designed siRNA Set A contains three designed siRNAs for NXF2 gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

NXF3 Human Pre-designed siRNA Set A contains three designed siRNAs for NXF3 gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

NXN Human Pre-designed siRNA Set A contains three designed siRNAs for NXN gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

NXNL1 Human Pre-designed siRNA Set A contains three designed siRNAs for NXNL1 gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

NXNL2 Human Pre-designed siRNA Set A contains three designed siRNAs for NXNL2 gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

NXPE3 Human Pre-designed siRNA Set A contains three designed siRNAs for NXPE3 gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

NXPH1 Human Pre-designed siRNA Set A contains three designed siRNAs for NXPH1 gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

NXPH3 Human Pre-designed siRNA Set A contains three designed siRNAs for NXPH3 gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

NXPH4 Human Pre-designed siRNA Set A contains three designed siRNAs for NXPH4 gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

NXT1 Human Pre-designed siRNA Set A contains three designed siRNAs for NXT1 gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

NXT2 Human Pre-designed siRNA Set A contains three designed siRNAs for NXT2 gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

NY0116 is a neuromedin U receptor 2 (NMUR2) agonist with EC50 values of 27.76 μM for hNMUR1 and 13.61 μM for hNMUR2. NY0116 decreases cAMP while stimulating calcium signaling in stably expressing NMUR2 HEK293 cells[1].

NYAP2 Human Pre-designed siRNA Set A contains three designed siRNAs for NYAP2 gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

NYNRIN Human Pre-designed siRNA Set A contains three designed siRNAs for NYNRIN gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

NYX Human Pre-designed siRNA Set A contains three designed siRNAs for NYX gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

NZ 419 (5-Hydroxy-1-methylhydantoin) is a metabolite of creatinine and an antioxidant with oral activity, which has the ability to scavenge hydroxyl radicals (•OH). NZ 419 can inhibit the progression of chronic kidney disease (CKD) in rats[1].

NZ-97 is an inhibitor for dipeptidyl peptidase 4 (DPP4) with an IC50 of 18 nM. NZ-97 exhibits a low initial plasma exposure with Cmax of 0.13 µM, which is eliminated in 8 h. NZ-97 ameliorates damage in the Lipopolysaccharide (HY-D1056)-induced lung injury and Bleomycin (HY-108345)-induced lung fibrosis in mice model[1].

Nε-(Carboxymethyl)-L-lysine (CML) is a unique post-translational modification (PTM) of proteins that is generated by the non-enzymatic glycation of lysine residues. Nε-(Carboxymethyl)-L-lysine is a relatively recently discovered modification, and has been found to be a major component of the advanced glycation endproducts (AGEs) found in multiple human diseases, such as diabetes, Alzheimer’s disease, and cancer[1].

Nε-(Carboxymethyl)-L-lysine (CML) is a unique post-translational modification (PTM) of proteins that is generated by the non-enzymatic glycation of lysine residues. Nε-(Carboxymethyl)-L-lysine is a relatively recently discovered modification, and has been found to be a major component of the advanced glycation endproducts (AGEs) found in multiple human diseases, such as diabetes, Alzheimer’s disease, and cancer[1].

O-Arachidonoyl glycidol (compound 1) is a 2-arachidonoylglycerol (2-AG) analog. O-Arachidonoyl glycidol inhibits cytosolic 2-oleoylglycerol (2-OG) hydrolysis with an IC50 value of 4.5 µM. O-Arachidonoyl glycidol blocks 2-OG hydrolysis in membrane fractions and anandamide hydrolysis with IC50s of 19, 12 µM, respectively[1].

o-Cresolphthalein complexone is a multifunctional dye. Dyes are important tools in biological experiments. They can help researchers observe and analyze cell structures, track biomolecules, evaluate cell functions, distinguish cell types, detect biomolecules, study tissue pathology and monitor microorganisms. Their applications range from basic scientific research to clinical A wide range of diagnostics. Dyes are also […]

O-Desmethyl quinidine (Cupreidine) is an orally active metabolite of Quinine (HY-D0143). O-Desmethyl quinidine reduces frequency of cramps in rats with spinal cord injury and shows low blood toxicity[1].

O-Desmethyl quinidine (Cupreidine) is an orally active metabolite of Quinine (HY-D0143). O-Desmethyl quinidine reduces frequency of cramps in rats with spinal cord injury and shows low blood toxicity[1].

O-Desmethyl quinidine (Cupreidine) is an orally active metabolite of Quinine (HY-D0143). O-Desmethyl quinidine reduces frequency of cramps in rats with spinal cord injury and shows low blood toxicity[1].

O-Methyldauricine ((-)-O-Methyldauricine) is an alkaloid with benzylisoquinoline group, which can be separated from P. ophthalmicus. O-Methyldauricine has antibacterial activity[1][2].

O’-(carboxymethyl)fluoresceinamide is a multifunctional dye. Dyes are important tools in biological experiments. They can help researchers observe and analyze cell structures, track biomolecules, evaluate cell functions, distinguish cell types, detect biomolecules, study tissue pathology and monitor microorganisms. Their applications range from basic scientific research to clinical A wide range of diagnostics. Dyes are also widely […]

OAF Human Pre-designed siRNA Set A contains three designed siRNAs for OAF gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

OARD1 Human Pre-designed siRNA Set A contains three designed siRNAs for OARD1 gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

OAS1 Human Pre-designed siRNA Set A contains three designed siRNAs for OAS1 gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

OAS2 Human Pre-designed siRNA Set A contains three designed siRNAs for OAS2 gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

OAS3 Human Pre-designed siRNA Set A contains three designed siRNAs for OAS3 gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

OASL Human Pre-designed siRNA Set A contains three designed siRNAs for OASL gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

OAT Human Pre-designed siRNA Set A contains three designed siRNAs for OAT gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

OAZ1 Human Pre-designed siRNA Set A contains three designed siRNAs for OAZ1 gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

OAZ3 Human Pre-designed siRNA Set A contains three designed siRNAs for OAZ3 gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

OBI1 Human Pre-designed siRNA Set A contains three designed siRNAs for OBI1 gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

OBP2A Human Pre-designed siRNA Set A contains three designed siRNAs for OBP2A gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

OBSCN Human Pre-designed siRNA Set A contains three designed siRNAs for OBSCN gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

Obscurolide A1 is a Phosphodiesterase (PDE) inhibitor (IC50=8 mM) that can be obtained from Streptomyces viridochromogenes culture. Obscurolide A1 has the potential to study neurological and inflammatory diseases[1].

OBSL1 Human Pre-designed siRNA Set A contains three designed siRNAs for OBSL1 gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

OC90 Human Pre-designed siRNA Set A contains three designed siRNAs for OC90 gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

OCA2 Human Pre-designed siRNA Set A contains three designed siRNAs for OCA2 gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

OCEL1 Human Pre-designed siRNA Set A contains three designed siRNAs for OCEL1 gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

OCIAD1 Human Pre-designed siRNA Set A contains three designed siRNAs for OCIAD1 gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

OCIAD2 Human Pre-designed siRNA Set A contains three designed siRNAs for OCIAD2 gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

CFI-400945 free base is a potent, selective and orally bioavailable PLK4 inhibitor with a Ki and an IC50 of 0.26 nM and 2.8 nM, respectively.